Rediff-TV 📺

This browser does not support the video element.

Disclaimer: This image is entirely AI-generated and is a product of artificial intelligence. Any resemblance to actual persons, whether living or deceased, is purely coincidental and unintentional.

1 month ago

Duration: 0h 4m 55s

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Name: Indian pharma eyes US gains as $63.7 bn patent cliff nears
Uploaded: Mon, 30 Jun 2025 12:31:49 +0530
Channel: Rediff Video Desk
Description: The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.

Uploaded by: Rediff Video Desk on Mon, 30 Jun 2025 12:31:49 +0530

Views: 0

Rediff-TV 📺

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Watch More Videos